During the consultation on the draft guidance Janssen, the manufacturer of the drug, submitted further information for the committee to consider.
This included a revised patient access scheme which involves providing the drug to the NHS at a discounted price, further information on which patients would benefit most and clarification on how many patients could receive the drug.
These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS.
More top news
He told People Magazine: "I was in denial, but a part of me always knew this was coming."
A compound within the Conus regius snail's venom has been found to create long-lasting pain relief.
NASA says the phenomenon is "quite unusual to see".